Revolution Medicines (RVMD) EBITDA (2019 - 2026)
Revolution Medicines (RVMD) posted EBITDA of -$505.1 million for Q2 2026, down 13.46% on a QoQ basis from -$445.2 million in Q1 2026, and down 90.82% year-over-year from -$5.5 billion in Q2 2025.
Powered by 
Analysis
Revolution Medicines (RVMD) EBITDA (2019 - 2026) Analysis & Trends
Revolution Medicines has reported EBITDA for 8 years, with the latest figure at -$505.1 million in Q2 2026.
- On a quarterly basis, EBITDA fell 90.82% year-over-year to -$505.1 million in Q2 2026; TTM through Jun 2026 was -$1.6 billion, a 81.31% decrease from a year earlier, with the FY2025 full-year figure at -$1.2 billion, down 71.48% from the prior year.
- EBITDA was -$505.1 million for Q2 2026 at Revolution Medicines, down from -$445.2 million in the prior quarter.
- The five-year high for EBITDA was -$57.9 million in Q1 2022, with the low at -$505.1 million in Q2 2026.
- Average EBITDA over 5 years is -$198.2 million, with a median of -$166.2 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2023: EBITDA retreated 16.62% in 2022, then tumbled 191.67% in 2023.
- Over 5 years, EBITDA stood at -$61.7 million in 2022, then sank by 191.67% to -$180.0 million in 2023, then declined by 20.18% to -$216.3 million in 2024, then tumbled by 67.18% to -$361.6 million in 2025, then slumped by 39.68% to -$505.1 million in 2026.
- The last three EBITDA figures came in at -$505.1 million (Q2 2026), -$445.2 million (Q1 2026), and -$361.6 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.01 Bn | 628.25 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 468.55 Bn | 462.03 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 365.49 Bn | 358.40 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 272.39 Bn | 265.10 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 253.18 Bn | 247.96 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 219.53 Bn | 205.54 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 187.85 Bn | 184.59 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 160.56 Bn | 149.16 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Vertex Pharmaceuticals | 130.81 Bn | 122.96 Bn | 2.84 Bn | 1.25 Bn |
| 10 | Revolution Medicines | 40.86 Bn | 40.86 Bn | - | -505.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -505.13 Mn |
| Mar 31, 2026 | -445.22 Mn |
| Dec 31, 2025 | -361.63 Mn |
| Sep 30, 2025 | -315.27 Mn |
| Jun 30, 2025 | -264.71 Mn |
| Mar 31, 2025 | -240.76 Mn |
| Dec 31, 2024 | -216.31 Mn |
| Sep 30, 2024 | -175.71 Mn |
| Jun 30, 2024 | -156.64 Mn |
| Mar 31, 2024 | -140.86 Mn |
| Dec 31, 2023 | -179.98 Mn |
| Sep 30, 2023 | -123.25 Mn |
| Jun 30, 2023 | -108.80 Mn |
| Mar 31, 2023 | -75.16 Mn |
| Dec 31, 2022 | -61.71 Mn |
| Sep 30, 2022 | -76.53 Mn |
| Jun 30, 2022 | -62.09 Mn |
| Mar 31, 2022 | -57.95 Mn |
| Dec 31, 2021 | -52.91 Mn |
| Sep 30, 2021 | -53.16 Mn |
API Access
Revolution Medicines EBITDA API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda&ticker=RVMD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda", "ticker": "RVMD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda&ticker=RVMD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();